Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 245247, 7 pages
http://dx.doi.org/10.1155/2014/245247
Clinical Study

Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study

1Division of Hematology, Department of Internal Medicine, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 137-701, Republic of Korea
2Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea
3Department of Hematology-Oncology, Chonnam National University Medical School, Jeollanam-do 519-763, Republic of Korea
4Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Republic of Korea
5Department of Internal Medicine, Yonsei University College of Medicine 120-752, Republic of Korea
6Department of Internal Medicine, Seoul National University College of Medicine, Seoul 110-744, Republic of Korea
7Department of Medicine, Korea University Medical Center, Seoul 136-705, Republic of Korea
8Department of Internal Medicine, Korea Cancer Center Hospital, Seoul 139-706, Republic of Korea
9Department of Internal Medicine, Pusan National University School of Medicine, Busan 602-739, Republic of Korea
10Inha University Hospital, Incheon 400-711, Republic of Korea
11Departments of Hematology/Oncology and Internal Medicine, Kosin University Gospel Hospital, Busan 602-702, Republic of Korea
12Department of Internal Medicine, Chonbuk National University Hospital, Jeonju 561-712, Republic of Korea
13Department of Internal Medicine, Inje University College of Medicine, Busan 612-896, Republic of Korea
14Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul 158-710, Republic of Korea
15Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon 310-721, Republic of Korea
16Department of Hematology-Oncology, Ajou University Hospital, Suwon 443-380, Republic of Korea
17Department of Internal Medicine, Chosun University College of Medicine, Gwangju 501-717, Republic of Korea
18Department of Internal Medicine, Dong-A University College of Medicine, Busan 602-715, Republic of Korea

Received 21 February 2014; Accepted 23 May 2014; Published 23 June 2014

Academic Editor: Dong Soon Lee

Copyright © 2014 Ki-Seong Eom et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Terpos, O. Sezer, P. Croucher, and M. Dimopoulos, “Myeloma bone disease and proteasome inhibition therapies,” Blood, vol. 110, no. 4, pp. 1098–1104, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Terpos, O. Sezer, P. I. Croucher et al., “The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network,” Annals of Oncology, vol. 20, no. 8, pp. 1303–1317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. R. Berenson, A. Lichtenstein, L. Porter et al., “Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events,” Journal of Clinical Oncology, vol. 16, no. 2, pp. 593–602, 1998. View at Google Scholar · View at Scopus
  4. J. R. Berenson, A. Lichtenstein, L. Porter et al., “Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma,” The New England Journal of Medicine, vol. 334, no. 8, pp. 488–493, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Major, A. Lortholary, J. Hon et al., “Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials,” Journal of Clinical Oncology, vol. 19, no. 2, pp. 558–567, 2001. View at Google Scholar · View at Scopus
  6. K. Zervas, E. Verrou, Z. Teleioudis et al., “Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients,” British Journal of Haematology, vol. 134, no. 6, pp. 620–623, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Giuliani, F. Morandi, S. Tagliaferri et al., “The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients,” Blood, vol. 110, no. 1, pp. 334–338, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. U. Heider, M. Kaiser, C. Müller et al., “Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment,” European Journal of Haematology, vol. 77, no. 3, pp. 233–238, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Min, M. Lee, K. Eom et al., “Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone,” Japanese Journal of Clinical Oncology, vol. 37, no. 12, pp. 961–968, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Lund, K. Søe, N. Abildgaard et al., “First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro,” European Journal of Haematology, vol. 85, no. 4, pp. 290–299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Terpos, D. J. Heath, A. Rahemtulla et al., “Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma,” British Journal of Haematology, vol. 135, no. 5, pp. 688–692, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Terpos, E. Kastritis, M. Roussou et al., “The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis,” Leukemia, vol. 22, no. 12, pp. 2247–2256, 2008. View at Publisher · View at Google Scholar
  13. G. L. Uy, R. Trivedi, S. Peles et al., “Bortezomib inhibits osteoclast activity in patients with multiple myeloma,” Clinical Lymphoma and Myeloma, vol. 7, no. 9, pp. 587–589, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Boissy, T. L. Andersen, T. Lund, K. Kupisiewicz, T. Plesner, and J. M. Delaissé, “Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions,” Leukemia Research, vol. 32, no. 11, pp. 1661–1668, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. I. von Metzler, H. Krebbel, M. Hecht et al., “Bortezomib inhibits human osteoclastogenesis,” Leukemia, vol. 21, no. 9, pp. 2025–2034, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. B. O. Oyajobi, I. R. Garrett, A. Gupta et al., “Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease,” British Journal of Haematology, vol. 139, no. 3, pp. 434–438, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Pennisi, X. Li, W. Ling, S. Khan, M. Zangari, and S. Yaccoby, “The proteasome Inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo,” American Journal of Hematology, vol. 84, no. 1, pp. 6–14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Terpos, D. Christoulas, P. Kokkoris et al., “Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid,” Annals of Oncology, vol. 21, no. 7, pp. 1561–1562, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Mukherjee, N. Raje, J. A. Schoonmaker et al., “Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice,” The Journal of Clinical Investigation, vol. 118, no. 2, pp. 491–504, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Ozaki, O. Tanaka, S. Fujii et al., “Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma,” International Journal of Hematology, vol. 86, no. 2, pp. 180–185, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Blade, D. Samson, D. Reece et al., “Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation,” British Journal of Haematology, vol. 102, no. 5, pp. 1115–1123, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. B. G. M. Durie, J.-L. Harousseau, J. S. Miguel et al., “International uniform response criteria for multiple myeloma,” Leukemia, vol. 20, no. 9, pp. 1467–1473, 2006. View at Publisher · View at Google Scholar
  23. E. Terpos, D. Christoulas, E. Kastritis et al., “Consolidation therapy with bortezomib, thalidomide and dexamethasone (VTD) regimen after asct in myeloma patients who do not receive bisphosphonates reduces bone resorption and is associated with low incidence of skeletal related events (SREs),” Haematologica, vol. 96, supplement 1, p. 126, 2011. View at Google Scholar
  24. M. Delforge, E. Terpos, P. G. Richardson et al., “Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma,” European Journal of Haematology, vol. 86, no. 5, pp. 372–384, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Zangari, D. Esseltine, F. Cavallo et al., “Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients,” American Journal of Hematology, vol. 82, no. 9, pp. 831–833, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. U. Heider, M. Kaiser, M. Mieth et al., “Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment,” European Journal of Haematology, vol. 82, no. 1, pp. 31–38, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Minisola, R. del Fiacco, S. Piemonte et al., “Biochemical markers in glucocorticoid-induced osteoporosis,” Journal of Endocrinological Investigation, vol. 31, supplement 7, pp. 28–32, 2008. View at Google Scholar · View at Scopus
  28. I. R. Reid, G. E. Chapman, T. R. C. Fraser et al., “Low serum osteocalcin levels in glucocorticoid-treated asthmatics,” Journal of Clinical Endocrinology and Metabolism, vol. 62, no. 2, pp. 379–383, 1986. View at Google Scholar · View at Scopus